2Heit JA. The epidemiology of venous thromboembolism in the community[J]. Arterioseler Thromb Vase Biol, 2008, 28: 370-372.
3International Union of Angiology. Prevention and treatment of venous thromboembolism. International Consensus Statement [J]. Int Angiol, 2006, 25: 101-161.
4Fraisse FHL, Couland JM, Simonneau G, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France[J].Am J Respir Crit Care Med, 2000, 161:1109-1114.
5Hirsh DR,Goldhaber SZ. Prevalence of deep venous thrombo- sis among patients in medical intensive care[J]. JAMA, 1995, 274 : 335-337.
6Spyropoulos AC. Emerging strategies in the prevention of ve- nous thromboembolism in hospitalized medical patients [J]. Chest, 2005, 128:958-969.
7Cohen AT, Arcelus JI. Assessment of venous thromboembo- lism risk and the benefits of thromboprophylaxis in medical pa- tients[J]. Thromb Haemost, 2005, 94:750-759.
8Lindblad BSN, Bergqvist D. Incidence of venous thromboembo- lism verified by necropsy over 30 years[J].[M], 1991, 302: 709-711.
9Heit JA, Mohr DN. Risk factors for deep vein thrombosis and pulmonaryembolism: a population-based case-control study[J]. Arch Intern Med, 2000, 160:809-815.
10Swayze OS, Nasser S, Roberson JR. Deep venous thrombosis intotal hip arthroplasty[J]. Orthop Clin North Am, 1992, 23 (2) :359-364.
3Alexander T Cohen,Bruce L Davidson,Alexander S Gallus,Michael R Lassen,Martin H Prins,Witold Tomkowski,Alexander G G Turpie,Jan F M Egberts,Anthonie W A Lensing,石汉平（译）,王深明（校）.Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究[J].英国医学杂志中文版,2006,9(5):282-285. 被引量：6
